Verastem Files Routine 8-K, Confirms Nasdaq Listing
Ticker: VSTM · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, compliance
TL;DR
**Verastem's 8-K is a routine filing, no major news.**
AI Summary
Verastem, Inc. filed an 8-K on January 29, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on The Nasdaq Capital Market under the ticker VSTM. This filing indicates routine compliance with SEC regulations, rather than a specific material event. For investors, this filing is a standard update, confirming the company's operational status and listing, and does not signal any immediate changes in its financial health or strategic direction.
Why It Matters
This filing is a standard regulatory update, confirming Verastem's listing on The Nasdaq Capital Market. It doesn't contain new material information that would immediately impact the stock price, but assures investors of continued compliance.
Risk Assessment
Risk Level: low — This 8-K is a standard compliance filing and does not introduce new risks or material changes to the company's operations or financial standing.
Analyst Insight
A smart investor would recognize this as a routine compliance filing with no immediate impact on investment decisions. It's a good reminder to check for more substantive filings like 10-Qs or 10-Ks for financial performance updates.
Key Numbers
- $0.0001 — par value per share (the stated par value of Verastem's common stock)
Key Players & Entities
- Verastem, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Capital Market (company) — the exchange where Verastem's common stock is registered
- VSTM (company) — the trading symbol for Verastem's common stock
- January 29, 2024 (date) — date of earliest event reported and filing date
- 001-35403 (dollar_amount) — Commission File Number
Forward-Looking Statements
- Verastem will continue to maintain its listing on The Nasdaq Capital Market. (Verastem, Inc.) — high confidence, target: 2025-01-29
FAQ
What is the primary purpose of this 8-K filing by Verastem, Inc.?
The primary purpose of this 8-K filing, dated January 29, 2024, is to provide general corporate information, confirm its registration under the Securities Exchange Act of 1934, and state that its common stock is listed on The Nasdaq Capital Market under the trading symbol VSTM.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 29, 2024.
What is the trading symbol and the exchange where Verastem, Inc.'s common stock is registered?
Verastem, Inc.'s common stock trades under the symbol VSTM and is registered on The Nasdaq Capital Market.
What is the par value per share of Verastem, Inc.'s common stock?
The par value per share of Verastem, Inc.'s common stock is $0.0001.
Is Verastem, Inc. considered an emerging growth company according to this filing?
No, the filing indicates with an 'o' that Verastem, Inc. is not checking the box for being an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Filing Stats: 414 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-01-29 16:01:10
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm244111d1_8k.htm (8-K) — 23KB
- tm244111d1_ex99-1.htm (EX-99.1) — 25KB
- tm244111d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-007712.txt ( ) — 230KB
- vstm-20240129.xsd (EX-101.SCH) — 3KB
- vstm-20240129_lab.xml (EX-101.LAB) — 33KB
- vstm-20240129_pre.xml (EX-101.PRE) — 22KB
- tm244111d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On January 29, 2024, Verastem, Inc. issued a press release outlining key 2024 strategic priorities and upcoming catalysts, a copy of which is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated January 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: January 29, 2024 By: /s/ Daniel W. Paterson Daniel W. Paterson Chief Executive Officer